Interesting to see the following in the report:
Phylogica is targeting cash sustainability in FY12 (ending June 2012).'
'Management remains confident in executing near-term deals based on its visibility on prospective deal flow and ongoing negotiations. We highlight that in previous years deals have been secured in the latter part of the year (possibly coinciding with budgetary cycles in large pharma research departments), so deals might materialise over the next few months.'
Add to My Watchlist
What is My Watchlist?
